Cerus Corp (CERS) Misses Q1 EPS by 10c, Comments on Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Cerus Corp (CERS) Enters INTERCEPT Blood System Agreement w/ Karolinska University Hospital
February 27, 2015 8:40 AM ESTCerus Corp (NASDAQ: CERS) announced that the Karolinska University Hospital (KUH) in Stockholm, has signed a three-year agreement to purchase the INTERCEPT Blood System for platelets. In addition to the three-year base term, the agreement allows for automatic annual extensions for an additional two years. KUH is Swedens largest platelet supplier and one of the largest University Hospitals in Europe, producing over 10,000 platelet units, or 20% of Swedens platelet... More
Cerus (CERS) PT Lowered to $6.50 at Wedbush Post Q4; 'Outperform' Maintained
February 27, 2015 7:16 AM ESTWedbush analyst Zarak Khurshid trimmed its price target on Cerus (NASDAQ: CERS) to $6.50 (from $7.50) but maintained an Outperform rating following results.
Khurshid notes, "Adjusted EPS loss roughly in-line. CERS reported 4Q14 sales of $9.7 MM and adjusted EPS loss of ($0.16), missing our $10.4 MM... More
